Main content

    Gynecologic Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Cervical Cancer  |  Endometrial Cancer  |  Ovarian / Fallopian tube / Peritoneal Cancer  |  All Tumor Types

    Active Trials

    Cervical Cancer

    Title: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
    Description: Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with pathologically confirmed primary cervical cancer initially treated with a standard radical hysterectomy with pelvic lymphadenectomy
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study GOG 263

    Title: Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 Cervical Cancer
    Description: Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with a histologic diagnosis of squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the cervix, stage IA1 (lymph-vascular space invasion [LVSI]+), IA2, and IB1 (tumor size [maximum visible or palpable]) =< 2 cm), any grade
    Status: Contact site for study status
    Contact: Kent Lai, 415-600-3613, Email: LaiKH@sutterhealth.org about Study GOG 278

    Title: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
    Description: This randomized phase III trial is studying chemotherapy and pelvic radiation therapy to see how well they work when given with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hysterectomy
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with histologically confirmed squamous, adenosquamous, or adenocarcinoma of the cervix
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study RTOG 0724

    Back to top

    Endometrial Cancer

    Title: A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer
    Description: The primary purpose of this study is to determine if MLN0128 in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Females, 18 years and older, with histologic or cytologic diagnosis of endometrial carcinoma (including endometrioid, serous, mixed adenocarcinoma, clear-cell carcinoma, or carcinosarcoma)
    Status: Active and open to enrollment
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study Millenium C31004

    Title: A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
    Description: Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with a histologically confirmed diagnosis of endometrial cancer and who must have undergone prior complete hysterectomy and bilateral salpingo-oophorectomy at the time of original therapy
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study GOG 238

    Back to top

    Ovarian / Fallopian tube / Peritoneal Cancer

    Title: FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer
    Description: This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Females, 18 years and older, diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer
    Status: Active and open to enrollment
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study Immunogen GOG3011

    Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
    Description: This study is a double-blind, randomized, placebo-controlled (2:1 niraparib:placebo) study in patients with Stage III or IV ovarian cancer.
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Females, 18 years and older, with histologically confirmed, advanced (FIGO Stage III or IV) high-grade predominantly serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have completed first line platinum based chemotherapy (neoadjuvant or adjuvant)
    Status: Active and open to enrollment
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study Tesaro PRIMA

    Title: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
    Description: This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory)
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, who have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of either serous or endometrioid cancer based on local histopathological findings
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study NRG-GY005

    Title: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
    Description: Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with a histological diagnosis of epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma, clinical stage II, III or IV at diagnosis
    Status: Contact site for study status
    Contact: Kent Lai, 415-600-3613, Email: LaiKH@sutterhealth.org about Study GOG 225

    Title: A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
    Description: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, with documented low-grade serous carcinoma; confirmation must occur by prospective pathology review prior to study entry; the prospective pathology review must be done on tissue from the recurrent carcinoma
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study GOG 281

    Title: A Single Arm, Open-label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women With Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation
    Description: This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell ovarian, fallopian tube or primary peritoneal carcinoma patients who have received at least 3 prior lines of chemotherapy and who do not carry deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutations.
    Investigator: AstraZeneca
    Eligibility: Females, 18 years and older, with histologically or cytologically-confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer that have recurrent platinum-resistant disease after at least 3 prior lines of chemotherapy, no BRCA mutation.
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study AZ CONCERTO

    Title: A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma With an Expansion in Select Malignancies
    Description: Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab. In the expansion stage of the study (Opened 2018), additional patients with epithelial ovarian carcinoma (EOC), melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), renal cell cancer (RCC), bladder cancer (BLC), or triple negative breast cancer (TNBC) will be treated.
    Investigator: Rgenix, Inc
    Eligibility: For Ovarian/Fallopian/Peritoneal Cancer: Females, 18 years and older, with histologically or cytologically-confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer which is recurrent or persistent Stage 3 or Stage 4
    Status: Contact site for study status
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study Rgenix
    Back to top

    All Tumor Types

    Title: An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
    Description: This is an open-label, multicenter, Phase I/II study to assess the safety, tolerability, and pharmacokinetics of GDC-0032. The Phase I portion will be divided into two stages. During Stage 1, GDC-0032 will be administered every day orally (PO) and at escalating doses in participants with locally advanced or metastatic solid tumors. During Stage 2, GDC-0032 will be administered alone or as combination therapy within indication-specific cohorts. In Phase II of the study, the efficacy and safety of the combination GDC-0032 and fulvestrant will be evaluated in post-menopausal female participants with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative, hormone receptor-positive breast cancer.
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Females, 18 years and older, who have histologically documented, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen and are not candidates for regimens known to provide clinical benefit
    Status: Active and open to enrollment
    Contact: Siu Chaw, 415-600-5772, Email: ChawS@sutterhealth.org about Study Genentech Phase I - PMT4979G

    Title: Molecular Analysis for Therapy Choice (MATCH)
    Description: This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists
    Investigator: NCI - National Cancer Institute
    Eligibility: Females, 18 years and older, who have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival
    Status: Contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study NCI-MATCH

    • updated 02/2018

    Back to top